We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 2.94% | 7.00 | 6.00 | 7.00 | 6.98 | 6.50 | 6.50 | 599,477 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 55.2M | -40.22M | -0.0084 | -7.74 | 324.12M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/9/2024 07:08 | Banjo/CoinThe longer term funding must be the priority do you think?jl | jimmyloser | |
18/9/2024 15:38 | Yes, I believe they maybe due. Perhaps next week. impo they could be the catalyst for the next step back up. | jimmyloser | |
18/9/2024 15:29 | Are the preliminary results due in next few weeks, if so that will be very interesting! | totally banjo | |
18/9/2024 14:33 | Plenty of potentially good news likely before then Let's hear that the cash is sortedThe market application inProgress in manufacturing and cost controlThe biomarkers are exceptional My own take is if all goes well then 7 p might be achieved.AGY need to deliver and whilst trials are going well, it is real tangible and exciting news that is needed here.Impo that is. | jimmyloser | |
18/9/2024 14:17 | Saying that, it's not long until December so we should see interest build as we near the initial results of the PROTECT trial and if positive then you would think double figures regarding the SP, imo | totally banjo | |
17/9/2024 23:15 | Yesterdays Cavendish coverage is basically just a repeat of the AGY update but saying that it's very positive that they appear to be working very well together in promoting the company! The initial coverage note is worth reading as it explains their view on where the company 'could' go if everything works out. As said before in the shorter term it's what happens regarding their current product line in Europe and elsewhere after the various manufacturing improvements, which should see an increase in revenue which will have a positive effect on the share price The products they offer are not just for the summer months as the allergies they protect from cover various causes and seasons, I assume there is a build up factor too for people with certain allergies but will have to look into that statement! | totally banjo | |
17/9/2024 13:25 | Yes, they’re very bullish. 4.075 GBX is peanuts! | coinbase | |
17/9/2024 13:12 | Hi CoinIt makes good reading. I see BLUE as I typeI should say that it is about timeImpo | jimmyloser | |
17/9/2024 11:59 | Jimmy, I’ve just read it. Thanks for pointing it out. | coinbase | |
17/9/2024 10:02 | I wasn't expecting an update on the PROTECT trial just yet so this is a bonus and great to hear that all is going to plan! | totally banjo | |
17/9/2024 09:22 | A very upbeat note from Cavendish this morningDyor etc | jimmyloser | |
17/9/2024 06:54 | That settles my nerves and hopefully our two key investors nerves too!I like the word 'keen' in Senor Llobets summaryThis is certainly encouraging news for those needing this product but still early days.Impo etc | jimmyloser | |
17/9/2024 06:31 | "Blood samples taken from peanut allergic study volunteers before and after dosing in cohorts 1 and 2 are being analysed to identify key biomarker changes indicative of efficacy. Basophil activation testing (BAT) mimics an allergic reaction by stimulating basophils with peanut allergens and then observing the expression of activation markers on the surface of the basophils. A reduction in the expression of those markers in the volunteers' samples would be indicative of efficacy in the VLP Peanut vaccine candidate. The preliminary results from the first two cohorts of peanut allergic patients are expected in Q4 2024." | coinbase | |
13/9/2024 18:44 | Jpuff,I may be wrong but from years ago those types of trades were deemed as a person moving from a normal trading account to an ISA, I'm sure someone will put me right :-) | totally banjo | |
13/9/2024 15:18 | The trades today - similar to some seen on previous days - show blocks two or paired buys at exactly the same time. So why are two 20k buys shown and not one 40k buy as there are several instances of this so can't be coincidence of different buyers? | jpuff | |
12/9/2024 17:27 | Yes jl, very interesting. | farmergeorge | |
12/9/2024 16:35 | I find this very interesting......... impo/etc. | jimmyloser | |
06/9/2024 18:39 | Hi Banjo, That is good work. I reckon that would qualify for being a ‘ BLOCKBUSTER’ size market by anyones reckoning, if they can pull this off. Jl | jimmyloser | |
06/9/2024 16:52 | Allergy Treatment Market Size and Share Projected to Surpass USD 34.9 Billion by 2034 at 5.8% CAGR - Report by Transparency Market Research, Inc. "Lastly, Allergy Therapeutics offers subcutaneous immunotherapy and sublingual immunotherapy. These are the key working verticals for the organization." hxxps://www.globenew hxxps://www.transpar | totally banjo | |
06/9/2024 12:45 | Cheap as chips Jimmy. Lots of madness in the current dysfunctional markets with AGY a good example. I'm personally looking forward to great returns here and remaining patient. | jpuff | |
06/9/2024 12:04 | Jimmy rides to our rescue and restores common sense. The price (if you believe)is just stupid impo/dyor et al | jimmyloser | |
05/9/2024 00:35 | Got beat 6-3 at pool tonight :-( but I won singles and doubles games :-) Anyway, in my opinion over the shorter term is seeing increased revenue in Europe due to their expanded manufacturing facilities to facility the demand for their existing products is key! There is so much potential (that word again) for this company to make massive gains for existing and new shareholders regarding the results of their various trials but they will take time (years) before they are revenue generating! If AGY issues the results of the PROTECT trial in Q4 2024 and if it's positive the share price will rocket! As said before, very boring stock to hold but could pay huge and I mean huge dividends from this current share price in a year or three or before if they get bought out! Do your own research as always! | totally banjo | |
04/9/2024 10:24 | The PROTECT trial estimated completion date is a few months into 2025 but this, I believe, is the follow up on subjects after the trial is finished. Therefore it is likely that we will get the results of the trial in Q4 2024 which will, if positive, give AGY exposure on the global stage which should be reflected in the share price I'm very positive for AGY future but it does need highlighting that the various on going trials will take time to become revenue generating. It is also quite possible AGY could be bought out before this time! | totally banjo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions